Shim Clinic Logo

Benign Prostatic Hyperplasia, Singapore - Shim Clinic

Benign prostatic hyperplasia


Latest News

Medical News Today: Six yoga poses for prostate enlargement
Mon, 18 Sep 2017 23:00:00 +0800 | Health News from Medical News Today
Yoga has many benefits, In this article, learn about six yoga poses that can help ease and manage the symptoms of benign prostatic hyperplasia. (Source: Health News from Medical News Today)

Merit Medical licenses KatGuide pleural drain tech from Pleuratech
Fri, 15 Sep 2017 22:49:37 +0800 | Mass Device
Merit Medical (NSDQ:MMSI) has licensed a novel surgical device designed to ensure drain placement in the pleural cavity from Pleuratech, according to a Young America Capital press release posted this week. The device is Denmark-based Pleuratech’s flagship product, the KatGuide, and is designed to guide chest tubes to the part of the pleural cavity which needs draining to reduce misplaced drains and increase surgical success rates. The companies did not release the exact terms of the deal, but said that it was a multimillion dollar license agreement, according to a press release. “As a leading manufacturer and marketer of proprietary disposable medical devices, Merit Medical Systems, Inc. is excited to add the KatGuide to our current portfolio of products.  This innovative med...

Photoselective Vaporization Bests Transurethral Resection of the Prostate for BPH Photoselective Vaporization Bests Transurethral Resection of the Prostate for BPH
Thu, 07 Sep 2017 00:57:54 +0800 | Medscape Medical News Headlines
Photoselective vaporization of the prostate (PVP) offers similar efficacy with better quality of life, compared with transurethral resection of the prostate (TURP), in men with benign prostatic hyperplasia (BPH), researchers from Italy report.Reuters Health Information (Source: Medscape Medical News Headlines)

How Teleflex Bagged a $1.1 Billion Hidden Treasure
Wed, 06 Sep 2017 02:21:56 +0800 | MDDI
Teleflex CEO Benson Smith expected some investors to be surprised by yet another billion-dollar acquisition, but sometimes businesses simply must strike while the iron is hot. The Wayne, PA-based company said it will buy NeoTract for up to $1.1 billion. The deal comes just seven months after Teleflex completed its $1 billion acquisition of Vascular Solutions. "I'm sure that at least some of you may be a bit surprised that Teleflex is once again active in M&A so quickly after announcing the acquisition of Vascular Solutions. Well, we are not," Smith said Tuesday during a conference call. Smith said Teleflex has made significant progress with the integration of Vascular Solutions, which he attributed largely to the company's business unit structure that allows one business to integrate a...

Teleflex to pay $1.1B for NeoTract
Tue, 05 Sep 2017 18:47:04 +0800 | Mass Device
Teleflex (NYSE:TFX) said today that it agreed to put up $1.1 billion to acquire NeoTract and its UroLift prostate treatment. The deal calls for an up-front cash payment of $725 million, plus another $375 million in milestone payments pegged to sales numbers through 2020, Wayne, Pa.-based Teleflex said. The deal is expected to close within 30 days. The UroLift system for benign prostate hyperplasia uses tiny devices that are inserted into the urethra in a minimally invasive procedure to reopen the lower urinary tract by pushing aside tissue from the enlarged prostate. NeoTract put up sales of roughly $51 million last year, up 178% over 2015, and is expected to post sales of $115 million to $120 million this year. “We are excited to announce this definitive agreement with NeoTrac...

NxThera adds $6m for Rez ūm prostate device
Fri, 21 Jul 2017 18:58:46 +0800 | Mass Device
NxThera said this week that it added another $6 million to its coffers in an ongoing round of debt financing. The Maple Grove, Minn.-based company is offering convertible promissory notes and Series C preferred stock warrants in the round, according to the filing, with the first sale logged Jan. 13. NxThera said it’s looking to raise an additional $5.8 million in the round, taking the total hoped-for raise from $15 million to $26.4 million. In Dec. 2015, Boston Scientific (NYSE:BSX) led a $40 million funding round for NxThera and its Rezūm device, saying it plans to boost its sales footprint in the U.S. and Europe. Backers Aberdare Ventures, Arboretum Ventures, GDN Holdings and The Ally Bridge Group also participated, NxThera said at the time. NxThera won CE Mark approval in the...

7 medtech stories we missed this week: July 7, 2017
Sat, 08 Jul 2017 00:16:26 +0800 | Mass Device
[Image from unsplash.com]From EnvisionTEC’s FDA approval to InVivo Therapeutics adding a new clinical site, here are seven medtech stories we missed this week but thought were still worth mentioning. 1. EnvisionTEC wins FDA nod for 3D printing E-Denture material EnvisionTEC announced in a June 30 press release that it has received FDA approval for its E-Denture material for 3D printing dentures. The company already has the E-Dent 100 and 400 materials approved for the printing of restorations that simulate teeth. The new approval makes EnvisionTEC the only 3D printing company worldwide that has a complete digital denture workflow solution. E-Denture will have a limited distribution in the third quarter and will be available in four natural shades. 2. Life Spine launches Osseo-Loc pro...

Tamsulosin and Naftopidil Offer Similar Benefits in BPH Tamsulosin and Naftopidil Offer Similar Benefits in BPH
Sat, 01 Jul 2017 01:39:51 +0800 | Medscape Medical News Headlines
Bladder storage symptoms associated with benign prostatic hyperplasia (BPH) improve to a similar extent with tamsulosin and naftopidil treatment, researchers from South Korea report.Reuters Health Information (Source: Medscape Medical News Headlines)

FDA grants de novo clearance for Merit Medical ’ s Embosphere
Fri, 23 Jun 2017 20:36:03 +0800 | Mass Device
Merit Medical (NSDQ:MMSI) said yesterday that its Embosphere device won expanded de novo clearance from the  to treat benign prostatic hyperplasia. The federal safety watchdog’s clearance means Embosphere can be used in prostatic artery embolization  procedures to treat BPH. “Merit’s Embosphere is the first embolic agent to receive FDA 513(f)(2) classification for prostatic artery embolization, providing a non-surgical treatment option for millions of men who suffer from BPH,” chairman & CEO Fred Lampropoulos said in prepared remarks. The device is designed to occlude the prostatic arteries to shrink the prostate and improve BPH symptoms, South Jordan, Utah-based Merit said. The post FDA grants de novo clearance for Merit Medical’s Embosphere appeared...

Popular prostate drug linked to serious side effects
Thu, 22 Jun 2017 11:00:00 +0800 | EurekAlert! - Medicine and Health
(Boston University Medical Center) Treatment of benign prostatic hyperplasia (BPH) with the commonly prescribed Avodart (Dutsteride) may put men at an increased risk for diabetes, elevated cholesterol levels, non-alcoholic fatty liver disease (NAFLD) and worsening erectile dysfunction. (Source: EurekAlert! - Medicine and Health)


Related Concepts


Private & Confidential Service